Arbutus Biopharma2015二季报有用信息

newchinabok

电脑坏了，yahoo去查吧

齐欢畅2

Arbutus Biopharma Announces Second Quarter 2015 Financial Results
Arbutus Biopharma Corporation
August 5, 2015 4:30 PM
GlobeNewswire

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced its second quarter 2015 unaudited financial results and provided a corporate update.

"We are very pleased with the considerable progress we have made in our business this quarter as we work to advance the development of our pipeline of HBV drug candidates, the largest portfolio in the industry" said Dr. Mark J. Murray, Arbutus' President and CEO. "We look forward to sharing new data on these programs as we proceed towards our goal of developing combination treatment regimens to improve the cure rate in HBV."

Recent Company Highlights

Arbutus Biopharma Corporation recently changed its corporate name from Tekmira Pharmaceuticals Corporation. This name change marks the successful integration of Tekmira and OnCore and reflects the new company's commitment to delivering a cure for chronic HBV.
The TKM-PLK1 Phase IIa clinical trial has been modified to study the effect of PLK1 on viral parameters in chronic HBV patients enrolled in the HCC trial. This is influenced by recent research that suggests PLK1 could have utility in treating HBV (Diab A. et al. Journal of Hepatology, April 2015).
Arbutus announced the formation of a discrete, independently financed business unit to manage, develop and maximize the value of Arbutus' non-HBV assets.
Arbutus announced the commitment to having at least four HBV product candidates advancing in clinical development in 1H16 and to filing three additional INDs for a cccDNA formation inhibitor, a core protein inhibitor (also known as capsid assembly inhibitor), and a surface antigen secretion inhibitor also in 2016.
Upcoming 2015 Pipeline Milestones

HBV Pipeline

2H15: Results from SAD trial of TKM-HBV, formulation selection
2H15: Initiate phase IIa, multi-dose efficacy study for TKM-HBV in chronic infected patients
4Q15: File IND for OCB-030

newchinabok

yes，就是这个信息

newchinabok

cccdna抑制剂，全世界唯一

齐欢畅2

不错的。

hao2014

也就是2a 啦

希望明年能有真正突破

老折腾

说得真好，就是看不懂

阳光醉人

杨梅生物制药公司宣布第二季度2015财务结果
杨梅生物制药公司
2015年8月5日下午4:30
群修

温哥华，不列颠哥伦比亚和美国，宾夕法尼亚州，2015年8月5日（GLOBE NEWSWIRE）——杨梅生物制药公司（ABUS），业界领先的治疗解决方案的公司，专注于开发用于治疗慢性乙型肝炎病毒感染（HBV），今天宣布其第二季度的2015未经审计的财务报告和提供企业更新。
“我们非常高兴我们有长足的进步，使我们的业务本季度我们的工作，推进我国HBV药物管道的发展，最大的组合在业内博士说：”马克J. Murray，杨梅的主席和首席执行官。”我们期待着分享新的数据，这些项目，我们继续我们的目标，发展联合治疗方案，以提高治愈率在乙肝病毒。”
最近公司亮点
杨梅生物制药公司最近改变了其公司的名字从Tekmira制药公司。这个名称的改变标志着Tekmira和核心的成功整合，反映了新公司致力于提供一种慢性乙型肝炎治疗。
的tkm-plk1 IIa期临床试验已被修改为研究慢性乙型肝炎患者纳入试验参数的影响肝癌的病毒基因。这是最近的研究表明在治疗乙肝有实用Plk1的可能影响（Diab A.等人。肝脏病杂志，四月2015）。
杨梅宣布一个离散的形成，独立融资的业务单元的管理，发展和杨梅非HBV资产价值最大化。
杨梅宣布承诺至少有四HBV的候选产品推进在1h16临床开发和申请额外的三条对cccDNA形成抑制剂，核心蛋白抑制剂（也被称为衣壳组装抑制剂），和表面抗原分泌抑制剂也在2016。
即将到来的2015个管道里程碑
乙型肝炎管道
2h15：从tkm-hbv伤心的试验结果，配方筛选
2h15：启动IIa期，在慢性感染的患者tkm-hbv多剂量的疗效研究
4q15：为ocb-030文件ind

9病成医

关于cccDNA抑制剂，有更详细的资料吗？

囧大叔

这是什么药，临床了吗？